Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship
S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community setting   XENLETA™ has a novel mechanism of action that is different than all other antibiotics, has been shown to be associated with a
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
-More than 200 hospital formulary reviews of XENLETA™ scheduled before the end of the year- -Approximately 50% of all covered lives have outpatient formulary access to XENLETA- - Initiating focused community sales efforts for XENLETA- -Conference call today at 4:30 p.m.
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019
DUBLIN, Ireland , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 2019
View HTML
Toggle Summary Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 clinical trials DUBLIN, Ireland , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacterial pneumonia (CABP)   DUBLIN, Ireland , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
View HTML
Toggle Summary Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
DUBLIN, Ireland , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive
View HTML
Toggle Summary Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.
First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship DUBLIN, Ireland , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com